JP2024514556A5 - - Google Patents
Info
- Publication number
- JP2024514556A5 JP2024514556A5 JP2023561129A JP2023561129A JP2024514556A5 JP 2024514556 A5 JP2024514556 A5 JP 2024514556A5 JP 2023561129 A JP2023561129 A JP 2023561129A JP 2023561129 A JP2023561129 A JP 2023561129A JP 2024514556 A5 JP2024514556 A5 JP 2024514556A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- acid sequence
- seq
- amino acid
- intracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/087475 | 2021-04-15 | ||
| CN2021087475 | 2021-04-15 | ||
| PCT/CN2022/087016 WO2022218402A1 (en) | 2021-04-15 | 2022-04-15 | Fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514556A JP2024514556A (ja) | 2024-04-02 |
| JP2024514556A5 true JP2024514556A5 (https=) | 2025-04-03 |
Family
ID=83640144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561129A Pending JP2024514556A (ja) | 2021-04-15 | 2022-04-15 | 融合タンパク質及びその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240366761A1 (https=) |
| EP (1) | EP4323412A4 (https=) |
| JP (1) | JP2024514556A (https=) |
| KR (1) | KR20240016246A (https=) |
| CN (1) | CN117157329A (https=) |
| AU (1) | AU2022259323B2 (https=) |
| CA (1) | CA3216173A1 (https=) |
| WO (1) | WO2022218402A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202317602A (zh) * | 2021-07-15 | 2023-05-01 | 福瑞德哈金森腫瘤中心 | 嵌合多肽 |
| WO2024103107A1 (en) * | 2022-11-14 | 2024-05-23 | Peter Maccallum Cancer Institute | Fusion proteins and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| MA46862A (fr) * | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| US11104732B2 (en) * | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
| CA3139011A1 (en) * | 2019-05-08 | 2020-11-12 | Medigene Immunotherapies Gmbh | Engineered t cells |
-
2022
- 2022-04-15 US US18/284,275 patent/US20240366761A1/en active Pending
- 2022-04-15 JP JP2023561129A patent/JP2024514556A/ja active Pending
- 2022-04-15 WO PCT/CN2022/087016 patent/WO2022218402A1/en not_active Ceased
- 2022-04-15 EP EP22787624.0A patent/EP4323412A4/en active Pending
- 2022-04-15 CN CN202280027642.3A patent/CN117157329A/zh active Pending
- 2022-04-15 AU AU2022259323A patent/AU2022259323B2/en active Active
- 2022-04-15 CA CA3216173A patent/CA3216173A1/en active Pending
- 2022-04-15 KR KR1020237033629A patent/KR20240016246A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| US20240024359A1 (en) | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 | |
| JP2023085527A5 (https=) | ||
| US11180553B2 (en) | Chimeric antigen receptor | |
| CN109415409B (zh) | Flag标记的cd19-car-t细胞 | |
| JP2024500847A5 (https=) | ||
| JP2021516996A5 (https=) | ||
| RU2020133171A (ru) | Биологически значимые ортогональные пары цитокинов/рецепторов | |
| US20190352409A1 (en) | Chimeric antigen receptor | |
| US20190338028A1 (en) | Cd47-car-t cells | |
| AU2019236307A1 (en) | Anti-GUCY2C chimeric antigen receptor compositions and methods | |
| TR201807939T4 (tr) | Kimerik antijen reseptörü. | |
| RS65343B1 (sr) | Ćelija | |
| US10934331B2 (en) | Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells | |
| CN110088124A (zh) | 与免疫球蛋白重链恒定区异源二聚体(异源二聚体Fc)融合的Il-21(异源二聚体Fc融合IL-21)以及包含其的药物组合物 | |
| CN108463469A (zh) | 一种与抗可替宁抗体连接的嵌合抗体受体及其用途 | |
| JP2024514556A5 (https=) | ||
| JP2023518293A5 (https=) | ||
| JP2024504728A5 (https=) | ||
| CN110475857B (zh) | 表达抗-可替宁嵌合抗原受体的天然杀伤细胞 | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| CN114615989A (zh) | 用于治疗癌症的靶向整联蛋白的打结素-fc融合体与抗cd47抗体的组合 | |
| WO2023246911A1 (zh) | 基于t细胞受体的双特异性多肽分子及其用途 | |
| JP2024535740A5 (https=) | ||
| TW202535921A (zh) | 用於靶向遞送免疫效應子細胞之試劑及方法 |